| Literature DB >> 2759344 |
M J Carter1, T J Facklam, P C Long, R A Scotland.
Abstract
The development of a genetically engineered human growth hormone (hGH) preparation is described. The cell line used to produce hGH is a C127 mouse cell transformed with a bovine papilloma virus (BPV) vector. Master, Extended Production, and Working Cell Banks were established. Product is produced by culturing in growth medium, and purified using a series of chromatography and ultrafiltration steps. Extensive testing of cell banks, and bulk and finished product reveals that the cells used to produce hGH are phenotypically and genotypically stable and are free from contamination with adventitious agents. Levels of residual host cell DNA are well below accepted guidelines. Clinical data gathered in multicenter trials confirm the efficacy and safety of the product in the treatment of classic growth hormone deficiency. The regulatory history of human growth hormone in the U.S. is reviewed.Entities:
Mesh:
Substances:
Year: 1989 PMID: 2759344
Source DB: PubMed Journal: Dev Biol Stand ISSN: 0301-5149